Maryland Becomes the First State to Cap What Government Health Plans Pay for Ozempic and Jardiance, Setting a $274 Monthly Limit That Could Reach Private Insurers by 2028

For years, state drug affordability boards have been more of a threat than a reality for pharmaceutical companies. That changed this week in Annapolis. Maryland’s Prescription Drug Affordability Board voted to set upper payment limits on two of the country’s best-selling diabetes medicines, Novo Nordisk’s Ozempic and Jardiance from Eli Lilly and Boehringer Ingelheim, making Maryland the first state to actually cap what its government health plans will pay for a brand-name drug.

The decision, reported by Bloomberg Law and WYPR, applies first to state and local government health plans. But the board’s own timeline points further: if the limits take effect as planned on Jan. 1, 2027, Maryland gains the ability to extend them to the private insurance market in 2028.

What the board decided

Under the vote, Maryland’s public-sector plans may pay $274 for a month’s supply of Ozempic, compared with a list price of roughly $1,000, according to Bloomberg Law. For Jardiance, the cap is $204 for a 30-day supply, below the $350 monthly list price Boehringer cites for patients paying without insurance.

Board staff estimate the move could save state and local governments about $6.1 million, WYPR reported. That is a modest figure on its own. The bigger number is what comes next: if the limits are extended to private insurance in 2028, the savings could rise to more than $150 million a year, according to the same report.

An upper payment limit is not a price control on the manufacturer’s list price. Drugmakers can still charge whatever they choose; the state simply refuses to reimburse more than the set amount. Vinny DeMarco, president of the Maryland Healthcare for All coalition, framed it to WYPR as the state telling manufacturers they can charge what they want, but Maryland will only pay what it considers reasonable. In most scenarios, the report notes, patients are not supposed to be billed for the difference; the gap is meant to be absorbed by the drug companies.

The pushback: access and pharmacy economics

Not everyone is convinced the savings will flow cleanly. Some pharmaceutical companies and patient advocacy groups argue upper payment limits may not lower what patients pay directly and could lead pharmacies to stop stocking the affected drugs if reimbursement falls below what they paid wholesalers. Aimed Alliance, a patient-access policy group, warned the board in written comments that limits could have downstream effects through formulary changes and utilization management, WYPR reported. The board has said it will revisit the policy if patient access appears to suffer.

Legal risk is the other shadow over the vote. Colorado’s affordability board set an upper payment limit on the autoimmune drug Enbrel in October 2025, scheduled to begin Jan. 1, 2027, but that limit is currently blocked by a preliminary injunction after the manufacturer sued in federal court, according to WYPR. A similar challenge in Maryland would be no surprise, and its outcome will determine whether other states feel confident enough to follow.

Why it matters for employers and insurers

The Maryland decision lands at a moment when every large buyer of health care is wrestling with the same question: what is a GLP-1 drug actually worth? A new CVS Health study released at the HLTH 2026 conference, reported by Fierce Healthcare, offers one answer. Using anonymized claims from Aetna’s fully insured members between 2023 and 2025, CVS found that patients who stayed on GLP-1 drugs for three years saw total medical spending fall by $9,400, while pharmacy spending rose by $13,300. The study estimated the drugs would pay for themselves at around $350 a month over three years.

The clinical benefits were real: CVS reported 34% to 42% fewer hospitalizations over three years and 14% lower odds of a serious cardiac event. But at current prices, the medical savings did not offset the drug spend. CVS chief medical officer Amy Compton-Phillips also pointed to employee turnover as a structural problem for employers, which may pay for the medication only to see a worker leave before the savings show up.

Put those findings next to Maryland’s numbers and the significance becomes clear. The state’s $274 cap for Ozempic sits below the roughly $350 break-even point CVS identified. If a government buyer can lock in that kind of price, self-insured employers, benefit consultants and pharmacy benefit managers will use it as a reference point in their own negotiations, whether or not the Maryland rule ever reaches the private market.

A template that could spread

Maryland is also looking to tie state limits to federal ones. Gov. Wes Moore and several lawmakers have signaled support for legislation that would let the board set upper payment limits on drugs where Medicare has already negotiated a “maximum fair price,” WYPR reported. There are already 25 drugs with negotiated prices, some taking effect in 2027, and the Centers for Medicare & Medicaid Services aims to set prices for another 15 by 2028.

That approach would sharply lower the administrative and legal burden for states, because the price benchmark would already be set by Washington. For drugmakers, it raises the prospect that Medicare’s negotiated prices will spill into state employee plans and, eventually, commercial coverage. For investors in pharmaceutical companies with large U.S. diabetes and obesity franchises, the long-term pricing outlook just became a little less certain.

What to watch

Three things will decide how much this vote matters. First, whether a manufacturer challenges the limits in court before Jan. 1, 2027, as happened in Colorado. Second, whether pharmacies in Maryland keep both drugs on their shelves once reimbursement changes. Third, whether the state follows through on extending limits to private insurance in 2028, which is where the savings estimate jumps from millions to more than $150 million a year.

For now, Maryland has done what no other state had managed: turned a long-debated affordability tool into an actual price ceiling on blockbuster drugs. Every employer, insurer and benefits buyer struggling with GLP-1 costs will be watching what happens next.

Sources: Bloomberg Law, WYPR (Nov. 17), Fierce Healthcare (Nov. 17).

Benefit changes mean more calls. When drug coverage shifts, members, patients and pharmacy customers pick up the phone. MAJ.COM Voice AI puts 24/7 AI voice agents on every inbound call and handles outbound sales and support, so your practice, pharmacy or plan never misses a lead.

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Coron @QUE.COM

Editor at QUE.com Intelligence.

coronquecom has 189 posts and counting.See all posts by coronquecom

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading